research A clinical case of familial alopecia areata in combination with immune pathology
Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab
Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
research 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
research Drugs affecting blood coagulation, fibrinolysis, and hemostasis
Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.
research Successful Hair Regrowth in Early Frontal Fibrosing Alopecia With Combination Therapy
Early combination therapy can effectively regrow hair in frontal fibrosing alopecia.
research Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment
The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
research Anidulafungin-Induced Alopecia
A woman's hair loss was probably caused by the antifungal drug anidulafungin.
research Frontal fibrosing alopecia: A multicenter review of 355 patients
The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis
A new engineered treatment shows promise in curing heart fibrosis.
research Flushing episodes in the context of frontal fibrosing alopecia with facial papules
A woman thought to have rosacea was actually suffering from Frontal Fibrosing Alopecia, a hair loss condition. Despite treatment, her condition didn't change, showing the importance of accurate early diagnosis.
research 5α-Reductase inhibitors in androgenetic alopecia
Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
research Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
research FINASTERIDE INFLUENCE ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY
Finasteride increases P-glycoprotein activity in the liver and kidney.
research Diagnostic and Therapeutic Assessment of Frontal Fibrosing Alopecia
The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research The Efficacy of Oral Finasteride and Dutasteride in the Treatment of Female Pattern Hair Loss and Frontal Fibrosing Alopecia in Women: A Scoping Review
Finasteride and dutasteride can improve hair loss in women, but more research is needed.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
research Actions of 5α-reductase inhibitors on the epididymis
5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
research Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study
Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research Oral dutasteride can be considered a first‐line treatment for frontal fibrosing alopecia until high‐quality clinical trials could show better results with other therapies
Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/research/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.